Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer

13 Dec 2016

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 27958297
DOI: 10.1038/nrclinonc.2016.191

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancerPMID 27958297Read ↗

Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.Semantic proximity Read ↗

Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease PreventionSemantic proximity Read ↗

Optimizing Ovarian Cancer Treatment and Prevention Through Parallel Germline and Somatic Genetic Testing.Semantic proximity Read ↗

Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.Semantic proximity Read ↗

FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing PracticesSemantic proximity Read ↗

PARP inhibitors in ovarian cancer: An overview of the practice‐changing trialsSemantic proximity Read ↗

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic PredispositionSemantic proximity Read ↗

Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapiesSemantic proximity Read ↗

Availability and payer coverage of BRCA1/2 tests and gene panels.Semantic proximity Read ↗

PARP inhibition outside of BRCA mutation carriers.Semantic proximity Read ↗

Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.Semantic proximity Read ↗

PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.